Apis Assay Technologies
Company Details
Status: Private
Employees: 101-250
Location:
Manchester, United Kingdom
Type:
sample
sample
sample
Technology:
sample
sample
sample
About: APIS is leveraging systems biology, interrogating multi-OMICs biodata, and deploying innovative ‘Clickmer’ ligand binding technology, for the validation and translation of biomarker and therapeutic assets into clinical utility.
APIS has deep expertise and capabilities in IVD development of molecular & immune assays for ultimate product realisation as diagnostic tests. In addition, APIS' expertise in bioinformatics and software development is offered as an agile service to our clients, to develop bespoke, end-to-end multi-OMICs solutions and platform development.
APIS has also developed a broad breast oncology product portfolio: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon - the new APIS PIK3CA Mutations Kit is a qPCR assay for the sensitive detection of key mutations in the PIK3CA gene.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Apis Assay Technologies | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.